What management recommendations are appropriate for a 68-year-old woman with normal cardiac evaluation, a coronary calcium score of 4 (no coronary artery disease), persistent angina, intolerance to isosorbide mononitrate, amlodipine, and metoprolol, and relief with sublingual nitroglycerin?

Management Recommendation

This patient most likely has angina with non-obstructive coronary arteries (ANOCA), specifically vasospastic angina or microvascular angina, and should be treated with a calcium channel blocker (such as diltiazem 30-60 mg three times daily or verapamil 40 mg twice daily, uptitrated as tolerated) as first-line therapy, with continued use of sublingual nitroglycerin as needed for acute episodes 1.

Clinical Reasoning

Understanding the Diagnosis

With a coronary calcium score of 4 (essentially no atherosclerotic disease), normal cardiac imaging, and negative ischemic evaluation, yet persistent angina that responds to sublingual nitroglycerin, this patient does not have obstructive coronary artery disease. The rapid relief with nitroglycerin (1-2 minutes) is characteristic of true angina 2, but the absence of anatomical disease points to a functional coronary disorder—either vasospastic angina or microvascular angina 1.

The 2023 AHA/ACC guidelines specifically address this clinical scenario under the INOCA (Ischemia with Non-Obstructive Coronary Arteries) framework 1. The response to nitroglycerin strongly suggests a vasomotor component to her symptoms.

Why Calcium Channel Blockers Are First-Line

For vasospastic angina, the 2023 AHA/ACC guidelines explicitly recommend calcium channel blockers as first-line therapy 1. This is critical because:

• Beta-blockers can worsen vasospastic angina by allowing unopposed alpha-adrenergic vasoconstriction
• She has already failed metoprolol (a beta-blocker), which may have actually exacerbated vasospasm
• Calcium channel blockers directly prevent coronary artery spasm and are the most effective agents for this condition

Specific Medication Recommendations

Start with a non-dihydropyridine calcium channel blocker:

• Verapamil 40 mg twice daily (uptitrate to 80-120 mg twice daily) OR
• Diltiazem 30-60 mg three times daily (uptitrate to 90 mg three times daily or use extended-release formulations)

These are preferred over dihydropyridines (like the amlodipine she failed) because they provide more consistent anti-vasospastic effects and better heart rate control 1.

If calcium channel blocker monotherapy is insufficient:

• Add a long-acting nitrate (isosorbide mononitrate 10 mg twice daily, uptitrated) 1
• However, she previously could not tolerate isosorbide mononitrate, so this may not be feasible
• Alternative second-line option: Consider ranolazine 500 mg twice daily (uptitrated to 1000 mg twice daily) 3, 4

Continue Sublingual Nitroglycerin

She should absolutely continue sublingual nitroglycerin 0.4 mg as needed for acute episodes 2, 5. The FDA labeling confirms this is appropriate for acute relief and prophylaxis before activities that may trigger angina 5. She can use it:

• At first sign of angina (repeat every 5 minutes up to 3 doses)
• Prophylactically 5-10 minutes before activities that typically trigger symptoms 5

Important Caveats and Pitfalls

Common mistakes to avoid:

1. Do not restart beta-blockers - These can worsen vasospastic angina and she has already failed metoprolol
2. Do not assume this is non-cardiac pain - Her response to nitroglycerin confirms the cardiac origin 2
3. Avoid excessive nitrate use - While sublingual nitroglycerin is appropriate for acute relief, chronic high-dose nitrate therapy can lead to tolerance 5, 6
4. Consider aspirin and statin cautiously - With a calcium score of 4 and no atherosclerotic disease, the benefit is less clear than in obstructive CAD, though the 2023 guidelines suggest considering these if there is any endothelial impairment 1

If Symptoms Persist Despite Optimal Medical Therapy

If she remains symptomatic on a calcium channel blocker:

1. Ensure adequate dosing (uptitrate to maximum tolerated dose)
2. Consider adding ranolazine as it works through a different mechanism 3, 4
3. Refer to an advanced heart failure/coronary specialist for consideration of invasive coronary function testing to definitively characterize her INOCA endotype (microvascular vs. vasospastic) 1
4. Consider trial of nicorandil if available (not currently in the United States) 1

Lifestyle and Risk Factor Management

Smoking cessation is absolutely critical if she smokes, as smoking is a major trigger for coronary vasospasm 1. Address other cardiovascular risk factors, though the prognostic benefit is less certain in the absence of atherosclerotic disease 7.